Resistance against novel anticancer metal compounds: differences and similarities.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Drug resistance updates

• Publication date

  2008-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.drup.2008.02.002PMID 18394950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Potentiation of arsenic trioxide cytotoxicity by Parthenolide and buthionine sulfoximine in murine and human leukemic cells

  2008cited by this paper
• Antitumour metal compounds: more than theme and variations.

  2008cited by this paper
• Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status

  2008cited by this paper
• Gold complexes as prospective metal-based anticancer drugs.

  2008cited by this paper
• Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells.

  2007cited by this paper
• ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions.

  2007cited by this paper
• Development of Gallium Compounds for Treatment of Lymphoma: Gallium Maltolate, a Novel Hydroxypyrone Gallium Compound, Induces Apoptosis and Circumvents Lymphoma Cell Resistance to Gallium Nitrate

  2007cited by this paper
• Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy.

  2007cited by this paper
• The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin

  2007cited by this paper
• NF‐κB as a potential molecular target for cancer therapy

  2007cited by this paper
• Non Platinum Metal Complexes as Anti‐cancer Drugs

  2007cited by this paper
• Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737.

  2007cited by this paper
• Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

  2007cited by this paper
• Development of ruthenium antitumor drugs that overcome multidrug resistance mechanisms.

  2007cited by this paper
• Isolation and characterization of arsenite resistant human epidermoid carcinoma KB cells

  2007cited by this paper
• Understanding the mechanisms of zinc-sensing by metal-response element binding transcription factor-1 (MTF-1).

  2007cited by this paper
• Molecular mechanisms of resistance and toxicity associated with platinating agents.

  2007cited by this paper
• Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.

  2007cited by this paper
• Therapeutic effect of arsenic trioxide (As2O3) on cervical cancer in vitro and In vivo through apoptosis induction

  2007cited by this paper
• Recent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers

  2007cited by this paper
• The Bcl-2 apoptotic switch in cancer development and therapy

  2007cited by this paper
• Gene expression analysis of gallium-resistant and gallium-sensitive lymphoma cells reveals a role for metal-responsive transcription factor-1, metallothionein-2A, and zinc transporter-1 in modulating the antineoplastic activity of gallium nitrate

  2007cited by this paper
• Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in high risk neuro-blastoma, with cell cycle and protein analyte correlates.

  2007cited by this paper
• Isolation and characterization of arsenite-resistant human epidermoid carcinoma KB cells.

  2007cited by this paper
• Preclinical antitumor activity of the oral platinum analog satraplatin

  2007cited by this paper
• Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

  2007cited by this paper
• NF-kappaB as a potential molecular target for cancer therapy.

  2007cited by this paper
• A critical role for IkappaB kinase beta in metallothionein-1 expression and protection against arsenic toxicity.

  2007cited by this paper
• Reversal of resistance to cytotoxic cancer therapies: DHMEQ as a chemo-sensitizing and immuno-sensitizing agent.

  2007cited by this paper
• Roots of imatinib resistance: a question of self-renewal?

  2007cited by this paper
• Mechanisms of resistance to cisplatin and carboplatin.

  2007cited by this paper
• Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide

  2007cited by this paper
• Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs.

  2007cited by this paper
• Organometallic Ruthenium Inhibitors of Glutathione‐S‐Transferase P1‐1 as Anticancer Drugs

  2007cited by this paper
• A Critical Role for IκB Kinase β in Metallothionein-1 Expression and Protection against Arsenic Toxicity*

  2007cited by this paper
• Establishment of an Arsenic Trioxide—Resistant Human Leukemia Cell Line That Shows Multidrug Resistance

  2007cited by this paper
• Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide

  2007cited by this paper
• Integration of steroid and growth factor pathways in breast cancer: focus on signal transducers and activators of transcription and their potential role in resistance.

  2007cited by this paper
• Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review.

  2007cited by this paper
• Arsenic trioxide induces p53-dependent apoptotic signals in myeloma cells with SiRNA-silenced p53: MAP kinase pathway is preferentially activated in cells expressing inactivated p53.

  2007cited by this paper
• Broadening the clinical use of platinum drug–based chemotherapy with new analogues

  2007influential reference
• Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

  2007cited by this paper
• The resurgence of platinum-based cancer chemotherapy

  2007influential reference
• Anticancer therapeutics: a surge of new developments increasingly target tumor and stroma.

  2007cited by this paper
• Reaction of Zn7metallothionein with cis- and trans-[Pt(N-donor)2Cl2] anticancer complexes: trans-Pt(II) complexes retain their N-donor ligands.

  2007cited by this paper
• Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.

  2007cited by this paper
• Multidrug-resistant cancer cells are preferential targets of the new antineoplastic lanthanum compound KP772 (FFC24).

  2007cited by this paper
• An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells.

  2007cited by this paper
• Bypass of DNA Lesions Generated During Anticancer Treatment with Cisplatin by DNA Polymerase η

  2007cited by this paper
• Arsenical-based cancer drugs.

  2007cited by this paper
• The roles of copper transporters in cisplatin resistance

  2007influential reference
• Increased cellular glutathione and protection by bone marrow stromal cells account for the resistance of non-acute promylocytic leukemia acute myeloid leukemia cells to arsenic trioxide in vivo

  2006cited by this paper
• Targeting multidrug resistance in cancer

  2006cited by this paper
• ATR, PML, and CHK2 Play a Role in Arsenic Trioxide-induced Apoptosis*

  2006cited by this paper
• Contribution of the Major Copper Influx Transporter CTR1 to the Cellular Accumulation of Cisplatin, Carboplatin, and Oxaliplatin

  2006cited by this paper
• Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.

  2006cited by this paper
• NF-κB: A Stress-Regulated Switch for Cell Survival

  2006cited by this paper
• Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin

  2006cited by this paper
• Redox behavior of tumor-inhibiting ruthenium(III) complexes and effects of physiological reductants on their binding to GMP.

  2006cited by this paper
• Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.

  2006influential reference
• On the potential of thioredoxin reductase inhibitors for cancer therapy.

  2006cited by this paper
• Peptide Folding, Metal-Binding Mechanisms, and Binding Site Structures in Metallothioneins

  2006cited by this paper
• NF-kappaB: a stress-regulated switch for cell survival.

  2006cited by this paper
• Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition

  2006cited by this paper
• Modulation of the cellular pharmacology of JM118, the major metabolite of satraplatin, by copper influx and efflux transporters

  2006cited by this paper
• Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy.

  2006cited by this paper
• Chronic exposure to methylated arsenicals stimulates arsenic excretion pathways and induces arsenic tolerance in rat liver cells.

  2006cited by this paper
• Enhanced Expression of Multidrug resistance-associated Protein 2 and Reduced Expression of Aquaglyceroporin 3 in an Arsenic-resistant Human Cell Line*

  2006cited by this paper
• Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study

  2006cited by this paper
• Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.

  2006cited by this paper
• Resistance to the Antineoplastic Agent Gallium Nitrate Results in Marked Alterations in Intracellular Iron and Gallium Trafficking: Identification of Novel Intermediates

  2006cited by this paper
• Arsenic Trioxide Affects Signal Transducer and Activator of Transcription Proteins through Alteration of Protein Tyrosine Kinase Phosphorylation

  2006cited by this paper
• Organometallic Chemistry, Biology and Medicine: Ruthenium Arene Anticancer Complexes

  2006cited by this paper
• DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity.

  2006cited by this paper
• Biological Consequences of Trinuclear Platinum Complexes: Comparison of [{trans-PtCl(NH3)2}2μ-(trans-Pt(NH3)2(H2N(CH2)6-NH2)2)]4+ (BBR 3464) with Its Noncovalent Congeners

  2006influential reference
• Molecular Aspects of Antitumor Effects of a New Platinum(IV) Drug

  2006cited by this paper
• The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo.

  2006cited by this paper
• Impaired cisplatin influx in an A2780 mutant cell line: Evidence for a putative, cis-configuration-specific, platinum influx transporter

  2006cited by this paper
• The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.

  2006cited by this paper
• Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells.

  2006cited by this paper
• Ruthenium complexes as anticancer agents.

  2006cited by this paper
• Differential effects of Stat3 inhibition in sparse vs confluent normal and breast cancer cells.

  2006influential reference
• Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine.

  2006cited by this paper
• Copper homeostasis in eukaryotes: teetering on a tightrope.

  2006cited by this paper
• From bench to bedside--preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A).

  2006cited by this paper
• Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug.

  2006cited by this paper
• Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer

  2006cited by this paper
• Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells.

  2006influential reference
• Anticancer activity of the lanthanum compound [tris(1,10-phenanthroline)lanthanum(III)]trithiocyanate (KP772; FFC24).

  2006cited by this paper
• Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175

  2005cited by this paper
• Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo

  2005cited by this paper
• Multidrug-resistant neuroblastoma cells are responsive to arsenic trioxide at both normoxia and hypoxia

  2005cited by this paper
• Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes.

  2005cited by this paper
• The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy

  2005cited by this paper
• Arsenic trioxide circumvents multidrug resistance based on different mechanisms in human leukemia cell lines.

  2005cited by this paper
• Early results from a phase I study on orally administered tris(8-quinolinolato)gallium(III) (FFC11, KP46) in patients with solid tumors--a CESAR study (Central European Society for Anticancer Drug Research--EWIV).

  2005cited by this paper
• Cisplatin Damage: Are DNA Repair Proteins Saviors or Traitors to the Cell?

  2005cited by this paper
• Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs.

  2005cited by this paper
• Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance.

  2005cited by this paper
• High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.

  2005cited by this paper

• Rational Design of Enzyme-Responsive Fluorescent Organoruthenium Prodrug for Real-Time Tracking of Cargo Release and Cytotoxicity.

  2026cites this paper
• Exploring the Structure–Activity Relationships of Albumin-Targeted Picoplatin-Based Platinum(IV) Prodrugs

  2025cites this paper
• Redefining platinum(IV) chemotherapy: α-tocopherol succinate functionalization and nanoparticle encapsulation to improve cisplatin- and oxaliplatin-based therapies.

  2025cites this paper
• Copper(I) complexes of a Triazine Derived Schiff Base: Synthesis, Crystal Structure and Biological Applications

  2025cites this paper
• A new fluorescent oxaliplatin(iv) complex with EGFR-inhibiting properties for the treatment of drug-resistant cancer cells

  2025cites this paper
• Novel Ruthenacarborane–NSAID Conjugates

  2025cites this paper
• Trans-Pd(II) complexes: A different approach for the development of promising anticancer drugs

  2025cites this paper
• Synthesis, Structure, and Stability of Copper(II) Complexes Containing Imidazoline-Phthalazine Ligands with Potential Anticancer Activity

  2025cites this paper
• Schiff bases and cancer drug resistance: key preclinical breakthroughs.

  2025cites this paper
• Anti-tumor activity of beauvericin: focus on intracellular signaling pathways

  2024cites this paper
• Ruthenium Complex Suppresses Proliferation of Residual Hepatocellular Carcinoma after Incomplete Radiofrequency Ablation Therapy.

  2024cites this paper
• Strategies for the Nuclear Delivery of Metal Complexes to Cancer Cells

  2024cites this paper
• Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer.

  2024cites this paper
• (2,6-Dimethylphenyl)arsonic Acid Induces Apoptosis through the Mitochondrial Pathway, Downregulates XIAP, and Overcomes Multidrug Resistance to Cytostatic Drugs in Leukemia and Lymphoma Cells In Vitro

  2024influential citation
• Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth—An Investigation of the Activation Mechanism and Their Nanoformulation

  2024cites this paper
• An overview of recent advancements in anticancer Pt(IV) prodrugs: New smart drug combinations, activation and delivery strategies

  2023cites this paper
• Influence of the Fatty Acid Metabolism on the Mode of Action of a Cisplatin(IV) Complex with Phenylbutyrate as Axial Ligands

  2023cites this paper
• Synthesis and structure of two novel trans-platinum complexes

  2023cites this paper
• Cytotoxicity and mechanism of action of metal complexes: An overview.

  2023cites this paper
• Tetranuclear Ru2Cu2 and Ru2Ni2 complexes with nanomolar anticancer activity.

  2023cites this paper
• Copper(II) Complexes with 1-(Isoquinolin-3-yl)heteroalkyl-2-ones: Synthesis, Structure and Evaluation of Anticancer, Antimicrobial and Antioxidant Potential

  2023cites this paper
• MeXpose—A Modular Imaging Pipeline for the Quantitative Assessment of Cellular Metal Bioaccumulation

  2023cites this paper
• Metallodrugs against Breast Cancer: Combining the Tamoxifen Vector with Platinum(II) and Palladium(II) Complexes

  2023cites this paper
• A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance

  2022cites this paper
• Oxidative Stress in Cancer Therapy: Friend or Enemy?

  2022cites this paper
• Investigation of the physico-chemical interaction of ct-DNA with Anticancer Glycine Derivative of Pt-complex by applying docking and MD simulation methods and multi-spectroscopic techniques

  2022cites this paper
• Copper (II) complexes based bis(pyrazolyl)borate derivatives as efficient anticancer agents: synthesis, characterization, X-ray structure, cytotoxicity, molecular docking and QSAR studies

  2022cites this paper
• Copper-Catalyzed Glutathione Oxidation is Accelerated by the Anticancer Thiosemicarbazone Dp44mT and Further Boosted at Lower pH

  2022cites this paper
• Anticancer Activity, Reduction Mechanism and G-Quadruplex DNA Binding of a Redox-Activated Platinum(IV)–Salphen Complex

  2022cites this paper
• Synthesis, Structure and Cytotoxic Properties of Copper(II) Complexes of 2-Iminocoumarins Bearing a 1,3,5-Triazine or Benzoxazole/Benzothiazole Moiety

  2022cites this paper
• Platinum(IV) Complexes of the 1,3,5-Triamino Analogue of the Biomolecule Cis-Inositol Designed as Innovative Antineoplastic Drug Candidates

  2022cites this paper
• Imidazole/4,4′-azopyridine bridging binuclear Ru(II) complexes: design, synthesis, bimolecular interactions and cytotoxicity against HeLa cell line

  2021cites this paper
• Methodology for characterization of platinum-based drug's targeted delivery nanosystems.

  2021cites this paper
• Bioinspired nonheme iron complex that triggers mitochondrial apoptotic signalling pathway specifically for colorectal cancer cells

  2021cites this paper
• Synthesis, characterisation and biological activity of the ruthenium(II) complexes of the N4-tetradentate (N4-TL), 1,6-di(2'-pyridyl)-2,5-dibenzyl-2,5-diazahexane (picenBz2).

  2021cites this paper
• Evaluation of the Anticancer and DNA-Binding Characteristics of Dichloro(diimine)zinc(II) Complexes

  2021cites this paper
• DNA-Binding and Cytotoxicity of Copper(I) Complexes Containing Functionalized Dipyridylphenazine Ligands

  2021cites this paper
• Structure–Activity Relationships of Triple-Action Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating Ligands

  2021cites this paper
• Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance.

  2021cites this paper
• Platinum-based chemotherapy via nanocarriers and co-delivery of multiple drugs.

  2021cites this paper
• Recent Advances in Zinc Oxide Nanoparticles (ZnO NPs) for Cancer Diagnosis, Target Drug Delivery, and Treatment

  2021influential citation
• Copper(II) Complexes Containing Natural Flavonoid Pomiferin Show Considerable In Vitro Cytotoxicity and Anti-inflammatory Effects

  2021cites this paper
• Anticancer Activity of Half-Sandwich Ru, Rh and Ir Complexes with Chrysin Derived Ligands: Strong Effect of the Side Chain in the Ligand and Influence of the Metal

  2021cites this paper
• Microwave-assisted synthesis of ruthenium(ii) complexes containing levofloxacin-induced G2/M phase arrest by triggering DNA damage

  2021cites this paper
• Effect of Net Charge on DNA-Binding, Protein-Binding and Anticancer Properties of Copper(I) Phosphine-Diimine Complexes

  2021cites this paper
• Potential of Metal Complexes for the Treatment of Cancer: Current Update and Future Prospective

  2021cites this paper
• DNA-Binding Capabilities and Anticancer Activities of Ruthenium(II) Cymene Complexes with (Poly)cyclic Aromatic Diamine Ligands

  2020cites this paper
• Nano-scale imaging of dual stable isotope labeled oxaliplatin in human colon cancer cells reveals the nucleolus as a putative node for therapeutic effect

  2020cites this paper
• Heterobinuclear copper(II)‑platinum(II) complexes with oxindolimine ligands: Interactions with DNA, and inhibition of kinase and alkaline phosphatase proteins.

  2020cites this paper
• Stability, Reduction, and Cytotoxicity of Platinum(IV) Anticancer Prodrugs Bearing Carbamate Axial Ligands: Comparison with Their Carboxylate Analogues.

  2020cites this paper
• p-Cymene metallo-derivatives: An overview on anticancer activity.

  2020cites this paper
• Synthesis, structures, DNA-binding, cytotoxicity and molecular docking of CuBr(PPh3)(diimine)

  2020cites this paper
• Exploring the DNA Binding Mechanisms of Platinum-Based Chemotherapeutic Agents: State of Art and Perspectives of the Candidates

  2020cites this paper
• DNA-Binding and Anticancer Activity of Binuclear Gold(I) Alkynyl Complexes with a Phenanthrenyl Bridging Ligand

  2020cites this paper
• Spectroscopic and biological properties of platinum complexes derived from 2-pyridyl Schiff bases

  2019cites this paper
• Mechanistic and structural basis for inhibition of copper trafficking by platinum anticancer drugs.

  2019cites this paper
• Synthesis and Cytotoxicity of Water-Soluble Dual- and Triple-Action Satraplatin Derivatives: Replacement of Equatorial Chlorides of Satraplatin by Acetates.

  2019cites this paper
• Biological properties of metal complexes of curcumin

  2019cites this paper
• Induction of transferrin aggregation by indazolium [tetrachlorobis(1H-indazole)ruthenate(iii)] (KP1019) and its biological function

  2019cites this paper
• Synthesis, structures, DNA-binding and anticancer activities of some copper(I)-phosphine complexes

  2019cites this paper
• pH and thermo dual stimulus‐responsive liposome nanoparticles for targeted delivery of platinum‐acridine hybrid agent

  2019cites this paper
• Ruthenium(ii) and palladium(ii) homo- and heterobimetallic complexes: synthesis, crystal structures, theoretical calculations and biological studies.

  2019cites this paper
• Oxidation of Human Copper Chaperone Atox1 and Disulfide Bond Cleavage by Cisplatin and Glutathione

  2019cites this paper
• Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics.

  2019cites this paper
• Bacterial ghosts as adjuvant to oxaliplatin chemotherapy in colorectal carcinomatosis

  2018cites this paper
• Cellular Pharmacology of Palladinum(III) Hematoporphyrin IX Complexes: Solution Stability, Antineoplastic and Apoptogenic Activity, DNA Binding, and Processing of DNA-Adducts

  2018cites this paper
• ATR-FTIR spectroscopy shows changes in ovarian cancer cells after incubation with novel organoamidoplatinum(ii) complexes.

  2018cites this paper
• Metal Drugs and the Anticancer Immune Response.

  2018cites this paper
• Altered membrane rigidity via enhanced endogenous cholesterol synthesis drives cancer cell resistance to destruxins

  2018cites this paper
• Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development

  2018influential citation
• Development of fluorescent platforms for the design of multifunctional compounds for in vitro and in vivo applications in molecular imaging

  2018cites this paper
• In search of new anticancer drug – Dimethylsulfoxide ruthenium(III) complex with bulky triazolopyrimidine derivative and preliminary studies towards understanding the mode of action

  2018cites this paper
• Hydrolysis in Acidic Environment and Degradation of Satraplatin: A Joint Experimental and Theoretical Investigation.

  2017cites this paper
• A systematic assessment of chemical, genetic, and epigenetic factors influencing the activity of anticancer drug KP1019 (FFC14A)

  2017cites this paper
• In vitro and in vivo anti-tumor effects of selected platinum(IV) and dinuclear platinum(II) complexes against lung cancer cells

  2017cites this paper
• Review: electrochemical studies on some metal complexes having anti-cancer activities

  2017cites this paper
• Antiproliferative Copper(II) and Platinum(II) Complexes with Bidentate N,N‐Donor Ligands

  2017cites this paper
• Synthesis, characterization and anticancer activity of new Schiff bases bearing neocryptolepine

  2017cites this paper
• The Natural Fungal Metabolite Beauvericin Exerts Anticancer Activity In Vivo: A Pre-Clinical Pilot Study

  2017cites this paper
• Platinum(IV) Complexes Featuring Axial Michael Acceptor Ligands – Synthesis, Characterization, and Cytotoxicity

  2017cites this paper
• An unsymmetric cisplatin-based Pt(iv) derivative containing 2-(2-propynyl)octanoate: a very efficient multi-action antitumor prodrug candidate.

  2017cites this paper
• Novel mononuclear Cu (II) terpyridine complexes: Impact of fused ring thiophene and thiazole head groups towards DNA/BSA interaction, cleavage and antiproliferative activity on HepG2 and triple negative CAL-51 cell line.

  2017cites this paper
• New planar trans-copper(II) β-dithioester chelate complexes: synthesis, characterization, anticancer activity and DNA-binding/cleavage studies

  2017cites this paper
• Spectroscopic and cytotoxic characteristics of (p-cymene)Ru(II) complexes with bidentate coumarins and density functional theory comparison with selected Pd(II) complexes

  2017cites this paper
• Facile synthesis of highly biocompatible folic acid-functionalised SiO2 nanoparticles encapsulating rare-earth metal complexes, and their application in targeted drug delivery.

  2017cites this paper
• Three structurally related Copper complexes with two isomers: DNA/BSA binding ability, DNA cleavage activity and excellent cytotoxicity

  2017cites this paper
• Copper(II) quinolinonato-7-carboxamido complexes as potent antitumor agents with broad spectra and selective effects

  2016cites this paper
• The synthesis, lipophilicity and cytotoxic effects of new ruthenium(II) arene complexes with chromone derivatives.

  2016cites this paper
• Thiomaltol-Based Organometallic Complexes with 1-Methylimidazole as Leaving Group: Synthesis, Stability, and Biological Behavior.

  2016cites this paper
• Platinum-based anticancer drugs encapsulated liposome and polymeric micelle formulation in clinical trials

  2016cites this paper
• Discovery of ‘click’ 1,2,3-triazolium salts as potential anticancer drugs

  2016cites this paper
• Magnesium, zinc, arsenic, selenium and platinum urinary excretion from cancer patients of Antofagasta region, Chile: multi-metal approach

  2016cites this paper
• Anticancer activity of a chelating nitrogen mustard bearing tetrachloridoplatinum(iv) complex: better stability yet equipotent to the Pt(ii) analogue.

  2016cites this paper
• Preparation and Biological Evaluation of Two Novel Platinum(II) Complexes Based on the Ligands of Dipicolyamine Bisphosphonate Esters

  2016cites this paper
• Synthesis of novel anticancer ruthenium-arene pyridinylmethylene scaffolds via three-component reaction.

  2016cites this paper
• Multi-scale imaging of anticancer platinum(iv) compounds in murine tumor and kidney

  2016cites this paper
• Low generation PAMAM dendrimers as drug carriers for Pt(IV) complexes

  2016cites this paper
• Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells

  2016cites this paper
• Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes.

  2016cites this paper
• Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy.

  2016cites this paper